Background Background: : Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease associated with psoriasis. PsA patients have a higher prevalence of some comorbidities (obesity, metabolic syndrome, depression and premature cardiovascular disease). Recent data suggest a link between fat-mediated inflammation and joint involvement in PsA. Visceral adiposity index (VAI) has been used as a surrogate of visceral adiposity.
Objectives Objective: To examine if VAI is correlated to disability and/or cutaneous involvement in PsA patients.
Methods Material and methods: Prospective study on 88 (37 M/51 W) consecutive PsA fulfilled CASPAR criteria. All the patients were evaluated according to a predefined protocol that included:rheumatology and dermatology clinical evaluation and functional disability ( Health Assessment Questionnaire, HAQ, quality of life score- Short Form36, SF36), PASI and VAI based on Waist Circumference (WC), Body Mass Index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels. BMI was calculeted in 4 standard categories according to WHO criteria and WC was calculeted according to WHO (cut points 94 cm for men and 80 cm for women).
Results Results: Our results demonstrated that WC was significantly associated with disability function (HAQ) even after adjustment for BMI; patients in the highest versus the lowest quartiles of WC had approximately 125% and 275% increases in the odds of HAQ among men and women, respectively (OR 2.33, 95% CI 1.08 to 4.66, OR 3.64, 95% CI 1.38 to 9.48). In contrast, there was no evidence of a significant association between HAQ and VAI index, with or without adjustment for WC.
Conclusions Conclusions: WC was found, independent of VAI, to be a risk factor for disability function in PSA patients among both men and women. Future evaluations are needed since some authors supported that abdominal obesity may also determine an increased risk of not achieving minimal disease activity in PsA patients, highlighting the role of abdominal fat accumulation as a negative predictor of good clinical response to biologic agents
Amato MC, Giordano C, Galia M et al:. Diabetes Care 2010, 33:920-922
Cañete JD, Mease P. Ann Rheum Dis. 2012 Aug;71(8):1265-6.
Taylor WJ. Curr Rheumatol Rep. 2012 Aug;14(4):369-74
Russolillo A, Iervolino S, Peluso et al. Rheumatology (Oxford). 2013 Jan;52(1):62-7
Disclosure of Interest None Declared